Provided by Tiger Fintech (Singapore) Pte. Ltd.

Merck

94.57
-0.1400-0.15%
Post-market: 94.660.0900+0.10%19:59 EDT
Volume:12.68M
Turnover:1.20B
Market Cap:238.89B
PE:14.03
High:94.88
Open:94.28
Low:93.45
Close:94.71
Loading ...

Guggenheim Adjusts Price Target on Merck & Co. to $115 From $122

MT Newswires Live
·
12 Feb

Neuphoria Therapeutics to Receive $15 Mln Payment from Merck

Dow Jones
·
12 Feb

Neuphoria Therapeutics Inc - Co Eligible for up to $450 Million in Additional Milestone Payments

THOMSON REUTERS
·
12 Feb

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

GlobeNewswire
·
12 Feb

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo

Benzinga
·
12 Feb

Jim Cramer on Merck & Co., Inc. (MRK): ‘Drug Stocks Are Really Getting Hurt’

Insider Monkey
·
11 Feb

HSBC Adjusts Price Target on Merck to $115 From $130

MT Newswires Live
·
11 Feb

Merck Says Health Canada Approves Keytruda for Non-Small Cell Lung Cancer

MT Newswires Live
·
11 Feb

Health Canada Approves Merck's Keytruda® (Pembrolizumab) for the Treatment of Adult Patients With Resectable Stage Ii, Iiia, or Iiib (T3-4N2) Non-Small Cell Lung Carcinoma (Nsclc) in Combination With Platinum-Containing Chemotherapy as Neoadjuvant Treatment, and Then Continued as Monotherapy as Adjuvant Treatment After Surgery

THOMSON REUTERS
·
11 Feb

Health Canada Approves Merck's KEYTRUDA® (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery

CNW Group
·
11 Feb

Buy Rating on Springworks Therapeutics Driven by Potential Merck Acquisition and Strong Drug Market Potential

TIPRANKS
·
11 Feb

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

Dow Jones
·
11 Feb

Merck (MRK) Downgraded by TD Cowen Over Keytruda, Gardasil Concerns

Insider Monkey
·
11 Feb

Pfizer, Astellas Cite 'Durable Benefit' in More Trial Results of Padcev Plus Keytruda in Urothelial Cancer

MT Newswires Live
·
11 Feb

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Business Wire
·
11 Feb

PRESS RELEASE: Eqs-Adhoc: Merck Kgaa Confirms Discussions With Springworks Therapeutics, Inc. On Potential Acquisition

Dow Jones
·
11 Feb